SI1105409T1 - Zascita endogenih peptidov pred peptidazno ucinkovitostjo s konjugacijo na krvne komponente - Google Patents

Zascita endogenih peptidov pred peptidazno ucinkovitostjo s konjugacijo na krvne komponente

Info

Publication number
SI1105409T1
SI1105409T1 SI200030836T SI200030836T SI1105409T1 SI 1105409 T1 SI1105409 T1 SI 1105409T1 SI 200030836 T SI200030836 T SI 200030836T SI 200030836 T SI200030836 T SI 200030836T SI 1105409 T1 SI1105409 T1 SI 1105409T1
Authority
SI
Slovenia
Prior art keywords
peptide
terminus
peptidase activity
amino acid
protection
Prior art date
Application number
SI200030836T
Other languages
English (en)
Inventor
Dominique P Bridon
Alan M Ezrin
Peter G Milner
Darren L Holmes
Karen Thibaudeau
Original Assignee
Conjuchem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Inc filed Critical Conjuchem Inc
Publication of SI1105409T1 publication Critical patent/SI1105409T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SI200030836T 1999-05-17 2000-05-17 Zascita endogenih peptidov pred peptidazno ucinkovitostjo s konjugacijo na krvne komponente SI1105409T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13440699P 1999-05-17 1999-05-17
US15340699P 1999-09-10 1999-09-10
US15978399P 1999-10-15 1999-10-15
PCT/US2000/013576 WO2000069900A2 (en) 1999-05-17 2000-05-17 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
EP00936023A EP1105409B1 (en) 1999-05-17 2000-05-17 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components

Publications (1)

Publication Number Publication Date
SI1105409T1 true SI1105409T1 (sl) 2006-06-30

Family

ID=27384581

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200030836T SI1105409T1 (sl) 1999-05-17 2000-05-17 Zascita endogenih peptidov pred peptidazno ucinkovitostjo s konjugacijo na krvne komponente

Country Status (11)

Country Link
EP (5) EP1105409B1 (sl)
JP (6) JP4217004B2 (sl)
AT (1) ATE318835T1 (sl)
AU (1) AU765753B2 (sl)
CA (4) CA2499211A1 (sl)
DE (1) DE60026300T2 (sl)
DK (1) DK1105409T3 (sl)
ES (1) ES2257298T3 (sl)
PT (1) PT1105409E (sl)
SI (1) SI1105409T1 (sl)
WO (1) WO2000069900A2 (sl)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
DE60006100T2 (de) 1999-05-17 2004-07-01 Conjuchem, Inc., Montreal Lang wirkende insulinotrope peptide
AU2002239414A1 (en) * 2000-11-02 2002-05-27 Bristol-Myers Squibb Company Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
AU2002233082B2 (en) * 2001-02-02 2005-11-10 Conjuchem Biotechnologies Inc. Long lasting growth hormone releasing factor derivatives
PT1360202E (pt) * 2001-02-16 2008-09-01 Conjuchem Biotechnologies Inc Peptídeo do tipo glucagon 2 (glp-2) de longa duração para o tratamento de doenças e distúrbios gastrointestinais
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
CA2444530A1 (en) * 2001-04-18 2002-10-24 The Open University Polypeptides, derivatives and uses thereof
US7491702B2 (en) 2001-04-18 2009-02-17 The Open University Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same
CA2447292A1 (en) * 2001-05-17 2002-11-21 Ceremedix, Inc. Peptide compounds for counteracting reactive oxygen species and free radicals
JP4463545B2 (ja) 2001-05-31 2010-05-19 コンジュケム バイオテクノロジーズ インコーポレイテッド Ｈｉｖ感染に対する長時間持続する融合ペプチドインヒビター
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
JP4235544B2 (ja) 2001-05-31 2009-03-11 アドライフ インコーポレーティッド 欠陥折畳み蛋白質センサー方法
AU2002240733B2 (en) * 2001-10-18 2009-04-09 Zlatko Ademovic Additive cytoprotective effects of two bioactive regions of pro-opiomelanocortin hormone
US6822073B2 (en) 2001-12-20 2004-11-23 Kimberly-Clark Worldwide, Inc. Modular peptide-based reagent
WO2003078460A1 (fr) * 2002-03-19 2003-09-25 Oncorex, Inc. Peptides, compositions medicinales contenant ce peptide et compositions medicinales anticancereuses
JP2004008027A (ja) * 2002-06-04 2004-01-15 Japan Science & Technology Corp ｃＡＭＰの産生活性を有する新規ペプチド
WO2004011595A2 (fr) * 2002-07-26 2004-02-05 Institut Pasteur Vecteurs destines au transfert de molecules d'interet dans des cellules cibles
EP1530588A2 (en) * 2002-07-31 2005-05-18 Conjuchem, Inc. Long lasting natriuretic peptide derivatives
BR0314657A (pt) * 2002-09-24 2005-08-02 Dong Xie Inibidores de fusão de derivados de peptìdeo de infecção de hiv
US7378495B2 (en) * 2002-10-21 2008-05-27 Pevion Biotech, Ltd. PTH-rP related peptide cancer therapeutics
AU2003290563A1 (en) * 2002-10-31 2004-05-25 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7462593B2 (en) 2002-11-07 2008-12-09 Us Gov Health & Human Serv Compositions and methods for promoting angiogenesis
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
ATE459370T1 (de) * 2002-11-26 2010-03-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
JP3974619B2 (ja) * 2003-01-10 2007-09-12 株式会社新潟ティーエルオー 遺伝子治療用ベクター及び該遺伝子治療用ベクターを投与された哺乳動物中又は培養細胞中の目的タンパク質の定量方法
CN1819839B (zh) * 2003-01-29 2010-06-09 李惟 免疫调节化合物和相关方法
DE10316583A1 (de) * 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
EP1620734A1 (en) * 2003-04-25 2006-02-01 Genova Ltd. Secreted polypeptide species reduced cardiovascular disorders
SI1648933T1 (sl) * 2003-07-25 2010-01-29 Conjuchem Biotechnologies Inc Dolgo delujoäś inzulinski derivat in metoda zanj
WO2005077094A2 (en) * 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
JPWO2005090399A1 (ja) * 2004-03-24 2008-05-08 財団法人岐阜県研究開発財団 各種細胞の増殖・分化を認識する抗体、その抗体を用いた増殖・分化の評価方法
JP5095391B2 (ja) * 2004-04-20 2012-12-12 スフィンゴテック・ゲーエムベーハー 医療診断におけるタキキニンの前駆体および／またはその断片の使用
JP4874954B2 (ja) 2004-04-21 2012-02-15 エノビア ファーマ インコーポレイティド 骨送達複合体ならびにタンパク質に骨を標的化させるためのその使用方法
JP4976282B2 (ja) * 2004-05-13 2012-07-18 ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー 医療診断におけるエンケファリンの前駆体および／またはその断片の使用
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
AU2012202855B2 (en) * 2004-09-03 2015-02-26 Philipps-Universitat Marburg GLP-1 and exendin related invention
CN101291683B (zh) * 2004-11-24 2011-08-17 纽普罗研究有限公司 治疗疾病的方法和组合物
JP4720175B2 (ja) * 2004-12-15 2011-07-13 富士ゼロックス株式会社 マレイミジル基含有材料およびその製造方法
DE102005003687A1 (de) 2005-01-26 2006-07-27 Sphingo Tec Gmbh Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation
CA2597912C (en) 2005-02-15 2013-06-04 Adlyfe, Inc. Method for detecting misfolded proteins and prions
WO2006108686A2 (en) * 2005-04-14 2006-10-19 Aic Bnp agonists
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
US20080292627A1 (en) * 2005-05-05 2008-11-27 The Board Of Trustees Of The University Of Illinois Compositions and Methods for Treating Mood and Anxiety Disorders
KR20080072639A (ko) * 2005-10-27 2008-08-06 주식회사 펩트론 생리활성 기질-혈액 단백질 복합체 및 이를 이용하는생리활성 기질의 안정화 방법
WO2007112453A2 (en) 2006-03-28 2007-10-04 Neopro Labs, Llc Methods amd compositions for treating conditions
US7982018B2 (en) 2006-10-16 2011-07-19 Conjuchem, Llc Modified corticotropin releasing factor peptides and uses thereof
WO2008052043A2 (en) * 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
US7803769B2 (en) 2006-10-25 2010-09-28 Amgen Inc. OSK1 peptide analogs and pharmaceutical compositions
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
EP2152725A1 (en) 2007-05-17 2010-02-17 Neopro Labs, LLC Crystalline and amorphous forms of peptide
US8420779B2 (en) 2007-05-22 2013-04-16 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
WO2009023125A1 (en) * 2007-08-14 2009-02-19 The Board Of Trustees Of The Leland Stanford Junior University Neuronostatin and its uses
RU2010113965A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Гамма-1-msh отдельно или в сочетании с пентагастрином в качестве терапевтического средства
US20100204138A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of trp6-triptorelin and d-leu6-leuprolide as therapeutic agents
KR20100059865A (ko) * 2007-09-11 2010-06-04 몬도바이오테크 래보래토리즈 아게 Ａｉｄｓ 또는 알츠하이머 병의 치료를 위한 치료제로서의 베타－멜라노트로핀의 용도
EP2187953A2 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of a peptide as a therapeutic agent
JP5588354B2 (ja) * 2008-02-01 2014-09-10 アセンディス ファーマ エー／エス 自己切断可能なリンカーを含むプロドラッグ
ES2563553T3 (es) 2008-04-01 2016-03-15 Novo Nordisk A/S Conjugados de insulina-albúmina
WO2009142727A2 (en) * 2008-05-19 2009-11-26 Vasogenix Pharmaceuticals, Inc. Sequence modified calcitonin gene related peptides (cgrp)
EP2401378B1 (en) 2009-02-25 2013-08-14 Merck Sharp & Dohme Corp. Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris
SG177592A1 (en) * 2009-07-29 2012-02-28 Daiichi Sankyo Co Ltd Motilin-like peptide compound having transmucosal absorbability imparted thereto
EP2459228B1 (en) 2009-07-31 2020-03-04 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an insulin linker conjugate
DK2459171T3 (en) 2009-07-31 2017-09-25 Sanofi Aventis Deutschland Long-acting insulin composition
US8815806B2 (en) 2009-10-28 2014-08-26 University Of Manitoba Yellow pea seed protein-derived peptides
BR112012020882A2 (pt) 2010-02-24 2015-11-03 Merck Sharp & Dohme métodos para produzir uma glicoproteína heteróloga e para produzir uma composição de glicoproteína, célula hospedeira, composição de glicoproteína, e, uso da pichia pastoris recombinante.
US20130143798A1 (en) * 2010-03-26 2013-06-06 Novo Nordisk A/S Novel glucagon analogues
JP2013535514A (ja) 2010-08-13 2013-09-12 エイルロン セラピューティクス，インコーポレイテッド ペプチド模倣大環状分子
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
JP6352806B2 (ja) 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
MX358886B (es) 2011-10-18 2018-08-31 Aileron Therapeutics Inc Macrociclos peptidomimeticos.
BR112014020103A2 (pt) 2012-02-15 2018-10-09 Aileron Therapeutics, Inc. macrociclos peptidomiméticos
CN108912211A (zh) 2012-02-15 2018-11-30 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
JP2013179884A (ja) * 2012-03-01 2013-09-12 Mitsubishi Rayon Co Ltd メラニンカスケードに関与する成分を評価するための核酸マイクロアレイ及びメラニンカスケードに関与する成分の評価方法
KR102238317B1 (ko) 2012-05-17 2021-04-12 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
WO2015001015A1 (en) * 2013-07-04 2015-01-08 Universitat De Barcelona Actively transported and protease-resistant peptides as bbb shuttles and shuttle-cargo constructs
EP3094643B1 (en) * 2014-01-15 2018-10-17 Fyziologicky ustav Akademie ved Ceske republiky, v.v.i. Lipidated peptides for lowering blood glucose
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
JP6946182B2 (ja) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ 治療用ビタミンｄコンジュゲート
RU2708068C2 (ru) 2014-12-05 2019-12-04 Алексион Фармасьютикалз, Инк. Лечение судорог с использованием рекомбинантной щелочной фосфатазы
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
US10308693B2 (en) * 2015-02-22 2019-06-04 Omnix Medical Ltd. Antimicrobial peptides
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11530243B2 (en) * 2016-02-18 2022-12-20 Veiove Animal Health Inc. Non-cleavable substance P conjugates and methods of use thereof
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
MX2018011833A (es) 2016-04-01 2019-02-13 Alexion Pharma Inc Tratamiento para la debilidad muscular con fosfatasas alcalinas.
EP3464573A4 (en) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. IMPACT OF METAL ON THE PRODUCTION OF ALKALINE PHOSPHATASES
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
WO2018221745A1 (ja) * 2017-06-02 2018-12-06 株式会社Ｌｓｉメディエンス 生体試料中からの標的タンパク質の抽出方法および標的タンパク質の分析方法
CN109503700A (zh) * 2017-09-14 2019-03-22 南京安吉生物科技有限公司 马来酰亚胺基团修饰的血管生成抑制剂hm-1及其应用
WO2019106193A1 (en) 2017-12-01 2019-06-06 University Of Copenhagen Peptide hormone with one or more o-glycans
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
WO2019197313A1 (en) 2018-04-09 2019-10-17 Svar Life Science Ab Glucagon Assay
IT202000007720A1 (it) * 2020-04-10 2021-10-10 Alessandra Marconi Peptidi e loro usi
JP2023550784A (ja) * 2020-11-25 2023-12-05 プロリンクス エルエルシー Ｃ－ナトリウム利尿ペプチドの徐放性ヒドロゲルコンジュゲート

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
BE795238A (fr) * 1972-02-09 1973-08-09 Schering Ag Derives d'insuline reticules de maniere intramoleculaire, leur procede de preparation et leur utilisation
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
DE3604868A1 (de) * 1986-02-15 1987-08-20 Behringwerke Ag Insulinderivate, verfahren zu ihrer herstellung und ihre verwendung
DD252539A1 (de) * 1986-09-17 1987-12-23 Berlin Chemie Veb Verfahren zur oralen anwendung biologisch aktiver peptide mit verzoegerter wirkung
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5422339A (en) * 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
CA2106314A1 (en) 1991-04-05 1992-10-06 John P. Burnier Platelet aggregation inhibitors having high specification for gpiibiiia
RU95106651A (ru) 1992-06-12 1996-12-27 Де-Тюр Дайнорфин Партнершип (US) Аналоги дзе-тур динорфина и способ лечения толерантных состояний у пациента
EP0602290B1 (en) * 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5446128A (en) * 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
WO1996006626A1 (en) 1994-08-26 1996-03-07 Lee Nancy M Analgesic method with dynorphin analogues truncated at the n-terminus
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
AU5850798A (en) * 1997-02-05 1998-08-26 1149336 Ontario Inc. Polynucleotides encoding proexendin, and methods and uses thereof
DE69806066T2 (de) * 1997-11-07 2003-02-06 Conjuchem Inc Affinitätsmarkierer für menschliches serum albumin
EP1028971A2 (en) * 1997-11-07 2000-08-23 ConjuChem, Inc. Novel conjugates of rgd-containing peptides and endogenous carriers
JP4394279B2 (ja) * 1998-03-09 2010-01-06 ジーランド ファーマ アクティーゼルスカブ 酵素加水分解に対する傾向が減少した薬理学的に活性なペプチド複合体
WO1999048536A2 (en) * 1998-03-23 1999-09-30 Conjuchem, Inc. Delivery of long lasting therapeutic agents by forming covalent attachments in vivo

Also Published As

Publication number Publication date
DK1105409T3 (da) 2006-07-03
JP2005239736A (ja) 2005-09-08
ATE318835T1 (de) 2006-03-15
EP1598365A1 (en) 2005-11-23
EP1623994A3 (en) 2008-07-16
JP2008150384A (ja) 2008-07-03
WO2000069900A9 (en) 2002-07-04
DE60026300D1 (de) 2006-04-27
WO2000069900A2 (en) 2000-11-23
EP1105409A2 (en) 2001-06-13
PT1105409E (pt) 2006-07-31
CA2499211A1 (en) 2000-11-23
EP2100901A1 (en) 2009-09-16
CA2373680C (en) 2008-07-29
JP2009079048A (ja) 2009-04-16
EP1591453A1 (en) 2005-11-02
DE60026300T2 (de) 2006-11-16
JP4221392B2 (ja) 2009-02-12
EP1623994A2 (en) 2006-02-08
AU5139300A (en) 2000-12-05
JP4217004B2 (ja) 2009-01-28
ES2257298T3 (es) 2006-08-01
JP2010168384A (ja) 2010-08-05
CA2505617A1 (en) 2000-11-23
CA2373680A1 (en) 2000-11-23
JP2003508350A (ja) 2003-03-04
EP1105409B1 (en) 2006-03-01
JP2005263807A (ja) 2005-09-29
AU765753B2 (en) 2003-09-25
WO2000069900A3 (en) 2001-02-15
CA2623458A1 (en) 2000-11-23
JP4219339B2 (ja) 2009-02-04

Similar Documents

Publication Publication Date Title
SI1105409T1 (sl) Zascita endogenih peptidov pred peptidazno ucinkovitostjo s konjugacijo na krvne komponente
SI1180121T1 (sl) Insulinotropni peptidi z dolgim delovanjem
EP0994724A4 (en) METHODS AND COMPOSITIONS TO PREVENT THE REPRODUCTION OF HIV-1
WO1996000503B1 (en) Novel peptides
CA2064689A1 (en) Stabilized protein or peptide conjugates
EP1982732A3 (en) Factor VII or VIIA-like conjugates
BG101077A (en) New peptides
PL312989A1 (en) Therapeutic derivatives of peptides
AUPP051497A0 (en) Antimicrobial peptides
UA65561A (en) Therapeutic agent for lymphatic tumors
AU703256B2 (en) Bradykinin analogs as selective thrombin inhibitors
NZ294397A (en) Cloning of an insulin-dependent membrane aminopeptidase designated GTVap from GLUT-4 vesicles
EP0759772A4 (en) TRI-, TETRA-, PENTA- AND POLYPEPTIDES AND THEIR THERAPEUTIC USE AS AN ANTIDEPRESSANT AGENT
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
MXPA04000339A (es) MeTODOS PARA REDUCIR INMUNOGENICIDAD DE POLIPePTIDOS.
TW200602353A (en) Modified secretin and method of synthesizing thereof
NZ501832A (en) Angiotensin-peptide carrier conjugates for treating diseases associated with the renin-angiotensin system
WO2005041882A3 (en) Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
WO2003087137A3 (en) New therapeutic uses of tri-, tetra-, penta-, and polypeptides
CA2078000A1 (en) Neutrophil stimulating peptides
IL150045A0 (en) Compositions and methods for detecting stress-inducible proteins
DE69827880D1 (de) Iga1-protease fragment als trägerpeptid
WO2002099379A3 (en) Breast homing peptides and methods of identifying same using aminopeptidase p
FR2787454B1 (fr) Inhibiteur de la topoisomerase ii
WO2001005420A8 (en) SMALL PEPTIDES AND METHODS FOR DOWNREGULATION OF IgE